Goodwin Procter advised Monte Rosa Therapeutics, while Paul Hastings advised TD Cowen and Wedbush PacGrow, as joint book-running managers, in the offering. Monte Rosa Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Goodwin advised Theseus Pharmaceuticals on the sale to Concentra Biosciences, assisted by Gibson, Dunn & Crutcher LLP. Leerink Partners acted as Theseus’ financial advisor. Theseus Pharmaceuticals,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised HOOKIPA, and Duane Morris advised the underwriters involved in the offering. HOOKIPA Pharma Inc. (Nasdaq: HOOK) announced its underwritten public offering of 22,900,768...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Avadel Pharmaceutics plc on the deal. Avadel Pharmaceuticals announced an underwritten public offering of 10,000,001 of its ordinary shares, nominal value $0.01 per...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BioDelivery Sciences International on the deal while Troutman Pepper advised Collegium Pharmaceutical. BioDelivery Sciences International (NASDAQ: BDSI) announced its definitive merger agreement to be...
You must be a Standard 1 Year member to access this content.
Cooley LLP advised Exscientia on the deal while Goodwin Procter represented Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, BofA Securities and Barclays Capital...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Omega Therapeutics, Inc. (Nasdaq: OMGA), a development-stage biotechnology company leveraging its OMEGA...
You must be a Standard 1 Year member to access this content.
Goodwin Procter and Baker McKenzie advised Trillium Therapeutics on the deal, while Ropes & Gray LLP and Norton Rose Fulbright Canada represented Pfizer. Trillium Therapeutics (NASDAQ/TSX:...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP and JunHe advised Goldman Sachs & Co. LLC and the other underwriters on the deal, while Wilson Sonsini Goodrich & Rosati and Maples...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Hogan Lovells and Cooley advised Valneva. Gide advised Goldman Sachs, Jefferies,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Vaccitech on the deal, while Davis Polk advised the representatives of the several underwriters. Vaccitech (Nasdaq: VACC) announced its initial public offering...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised CRISPR Therapeutics on the deal. CRISPR Therapeutics (NASDAQ: CRSP) announced its collaboration agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to develop, manufacture, and...
You must be a Standard 1 Year member to access this content.
